- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-33-0013568

Nakoda Pharma Private Limited
About Nakoda Pharma Private Limited
Data last updated:
Nakoda Pharma Private Limited is a private limited company based in Thane, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 23 August 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2020PTC344302. Its GSTIN is 27AAHCN1087G1ZD (Maharashtra).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors including Hetal Jaipal Rajawat and Manisha Kalpesh Rajawat.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Thane, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹3.55 Cr, a decline of 39% compared to the previous year. For the same year it recorded a net profit of ₹8.13 Lakh (net margin 2.3%) and EBITDA of ₹11.98 Lakh (EBITDA margin 3.4%). Revenue has grown at a compounded annual rate (CAGR) of 32% over three years.
As per MCA filings, the company has open charges of ₹40 Lakh on record.
Nakoda Pharma Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0013568).
Company details
Recognitions & Rankings of Nakoda Pharma
Contact details
Nakoda Pharma Private Limited's registered office is in Thane, Maharashtra.
- Registered AddressShop No 9 And 10 Sector No IX B – 6 Shanti Nagar Next To Vardhaman Medical M, Ira Road E, Thane, Maharashtra, India – 401107
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Nakoda Pharma is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of Nakoda Pharma Private Limited, buy the company report.
Financials of Nakoda Pharma Private Limited
FY 2025 filings availableNakoda Pharma Private Limited reported revenue of ₹3.55 Cr (down 39% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 39% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 32%. EBITDA rose 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹11.98 Lakh | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ₹8.13 Lakh | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 3.4% | |||
| Net Profit Margin | 2.3% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Nakoda Pharma Private Limited, buy the company report.
Board of directors of Nakoda Pharma Private Limited
Nakoda Pharma has 4 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hetal Jaipal Rajawat | Director | 26 Aug 2020 | 6 Years 1 Months | Current |
| Manisha Kalpesh Rajawat | Director | 23 Aug 2020 | 6 Years 2 Months | Current |
| Jaipal Vimal Rajawat | Director | 23 Aug 2020 | 6 Years 2 Months | Current |
| Kalpesh Vimalchand Rajawat | Director | 23 Aug 2020 | 6 Years 2 Months | Current |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Nov 2020 | 100386827 | Canara Bank | ₹40 Lakh | Open |
To see the full charge records of Nakoda Pharma Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Nakoda Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nakoda Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Nakoda Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAHCN1087G1ZD | Maharashtra | Active | 12 Oct 2020 |
To see the full GST registrations and return filing status of Nakoda Pharma Private Limited, buy the company report.
Recent activity
Nakoda Pharma Private Limited has 4 board changes on record since 2020: 4 appointments. The latest: Hetal Jaipal Rajawat was appointed as Director on 26 Aug 2020.
Frequently asked questions
Nakoda Pharma is an active private limited company based in Thane, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 23 August 2020 (6+ years old) and is registered under CIN U51909MH2020PTC344302.
Nakoda Pharma has 4 current directors:
- Hetal Jaipal Rajawat - Director
- Manisha Kalpesh Rajawat - Director
- Jaipal Vimal Rajawat - Director
- Kalpesh Vimalchand Rajawat - Director
The latest financial statements of Nakoda Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Nakoda Pharma is 27AAHCN1087G1ZD, registered in Maharashtra.
The CIN (Corporate Identification Number) of Nakoda Pharma is U51909MH2020PTC344302. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nakoda Pharma was incorporated on 23 August 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
Hetal Jaipal Rajawat was appointed as Director on 26 Aug 2020. Jaipal Vimal Rajawat was appointed as Director on 23 Aug 2020. Kalpesh Vimalchand Rajawat was appointed as Director on 23 Aug 2020. Nakoda Pharma has 4 board changes on record in total.
Yes, Nakoda Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0013568).
The registered office of Nakoda Pharma is at Shop No 9 And 10 Sector No IX B – 6 Shanti Nagar Next To Vardhaman Medical M, Ira Road E, Thane, Maharashtra, India – 401107.
Nakoda Pharma operates in the pharma industry, in the pharmaceutical retailers and distributors segment.